Allo-SCT for multiple myeloma: A review of outcomes at a single transplant center

Bone Marrow Transplantation

Volumn 47, Issue 10, 2012, Pages 1312-1317

  Bensinger, W ^a   Rotta, M ^a   Storer, B ^a   Chauncey, T ^a   Holmberg, L ^a   Becker, P ^a   Sandmaier, B M ^a   Storb, R ^a   Maloney, D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Allo stem cell transplant; Allogeneic BM transplant; Multiple myeloma; Plasma cell disorders

Indexed keywords

BETA 2 MICROGLOBULIN; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOGRAFT; CANCER GROWTH; CANCER RECURRENCE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; REVIEW; WHOLE BODY RADIATION;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84867396509     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.1     Document Type: Review

References (34)

1. Anderson KC. The role of immunomodulatory drugs in multiple myeloma (Review). Semin Hematol 2003; 40: 23-32.
2. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
3. Lacy M, Gertz M, Dispenzieri A, Hayman S, Geyer S, Zeldenrust S et al. Lenalidomide plus dexamethasone (Rev/Dex) in newly diagnosed myeloma: response to therapy, time to progression, and survival. Blood 2006; 108(Part 1): 239a, #798.
4. Attal M, Harousseau J-L, Stoppa A-M, Sotto J-J, Fuzibet J-G, Rossi J-F et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
5. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
6. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227-9233.
7. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2526.
8. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versusmyeloma effect: proof of principle. Blood 1996; 87: 1196-1198.
9. Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17: 208-215.
10. Kroger N, Badbaran A, Lioznov M, Schwarz S, Zeschke S, Hildebrand Y et al. Posttransplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol 2009; 37: 791-798.
11. Bensinger WI, Buckner CD, Anasetti C, Clift R, Storb R, Barnett T et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787-2793.
12. Gahrton G, Svensson H, Cavo M, Apperley J, Bacigalupo A, Björkstand B et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983 - 93 and 1994 - 98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209-216.
13. Anderson KC. Who benefits from high-dose therapy for multiple myeloma? (editorial; comment). J Clin Oncol 1995; 13: 1291-1296.
14. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-3454.
15. Einsele H, Schafer HJ, Hebart H, Bader P, Meisner C, Plasswilm L et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reducedintensity conditioning. Br J Haematol 2003; 121: 411-418.
16. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110-1120.
17. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107: 3474-3480.
18. Rosiñol L, Pérez-Simón JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008; 112: 3591-3593.
19. Bjorkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011; 29: 3016-3022.
20. Krishnan A, Pasquini MC, Ewell M, Stadtmauer EA, Alyea III EP, Antin JH et al. Tandem autologous hematopoietic stem cell transplants (AuHCT) with or without maintenance therapy (auto-auto) versus single AuHCT followed by HLA matched sibling non- myeloablative allogeneic HCT (auto-allo) for patients with standard risk (SR) multiple myeloma (MM); results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 trial. Blood 2010; 116: 24 - 25, #41.
21. Crawley C, Iacobelli S, Björkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007; 109: 3588-3594.
22. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
23. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma [Erratum appears in Leukemia. 2007 May;21(5):1134] [Erratum appears in Leukemia. 2006 Dec;20(12):2220]. Leukemia 2006; 20: 1467-1473.
24. Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 115: 4715-4726.
25. Gahrton G, Iacobelli S, Bandini G, Bjorkstrand B, Corradini P, Crawley C et al. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Haematologica 2007; 92: 1513-1518.
26. Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755-760.
27. Kröger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004; 10: 698-708.
28. Schilling G, Hansen T, Shimoni A, Zabelina T, Simon-Perez JA, Gutierrez NC et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2008; 22: 1250-1255.
29. Klyuchnikov E, Sputtek A, Slesarchuk O, Lioznov M, Stübig T, Bacher U et al. Purification of CD4(+) T cells for adoptive immunotherapy after allogeneic hematopoeitic stem cell transplantation. Biol Blood Marrow Transplant 2010; 17: 374-383.
30. Rizzieri DA, Storms R, Chen DF, Long G, Yang Y, Nikcevich DA et al. Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 1107-1114.
31. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008; 143: 641-653.
32. Attal M, Harousseau JL, Marit G, Caillot D, Stoppa AM, Benboubker L et al. Lenalidomide after autologous transplantation for myeloma: first analysis of a prospective, randomized study of the Intergroupe Francophone Du Myelome (IFM 2005 02). Blood 2009; 114: 220-221.
33. McCarthy PL, Owzar K, Stadtmauer EA, Giralt S, Hurd DD, Hassoun H et al. Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma (CALBG 100104): initial reprot of patient accrual and adverse events. Blood 2009; 114: 1327.
34. Jakubowiak AJ, Bensinger W, Siegel D, Zimmerman TM, Van Tornout JM, Zhao C et al. Phase 1/2 study of elotuzumab in combination with bortezomib in patients with multiple myeloma with one to three prior therapies: interim results. Blood 2009; 114: 1491-1492.